Bayer, Schrödinger partner on compound developing software project

By Vassia Barba

- Last updated on GMT

(Image: Getty/Rost-9D)
(Image: Getty/Rost-9D)

Related tags Bayer Schrödinger Software data analysis Data management machine learning Artificial intelligence

Bayer to work with Schrödinger on a molecule design software, which will be integrated into the latter’s LiveDesign, a digital drug design platform.

Under the five-year collaboration agreement, Bayer and Schrödinger aim to develop a virtual platform, which will be able to enumerate, screen and design synthetically feasible compounds – potentially leading to the development and optimization of new therapeutic candidates.

The collaborative work will be based on Schrödinger’s molecular design technology and machine learning capabilities, while Bayer, on its side, will provide the in silico​ models that are able to predict the absorption, distribution, metabolism, excretion, toxicity and chemical synthesizability of the compounds.

A spokesperson for the company could not specify the therapeutic target areas that will be worked on through this partnership.

The software will be built leveraging Schrödinger’s LiveDesign platform, a digital platform enabling the in silico ​design of therapeutic candidates.

On its website, Schrödinger states that its platform is capable of evaluating billions of molecules per week with a high degree of accuracy.

The most ‘promising’ compounds that emerge from each round of experimental project chemistry conducted on Schrödinger’s platform are subsequently optimized through additional cycles of computation analysis.

Earlier this year, Schrödinger announced an extension​ of its collaborative work with Morphic Therapeutic on the development of treatments for fibrosis, Crohn’s disease, and inflammatory bowel disease.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us